Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
9.43
+0.25 (2.72%)
At close: May 28, 2025, 4:00 PM
9.40
-0.03 (-0.32%)
After-hours: May 28, 2025, 4:41 PM EDT
Stoke Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Stoke Therapeutics stock ranges from a low of $17 to a high of $35. The average analyst price target of $24.5 forecasts a 159.81% increase in the stock price over the next year.
Price Target: $24.50 (+159.81%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $35 | Strong Buy | Maintains | $47 → $35 | +271.16% | May 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +133.30% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +398.41% | Mar 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +154.51% | Mar 19, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +133.30% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
52.70M
from 36.56M
Increased by 44.17%
Revenue Next Year
63.24M
from 52.70M
Increased by 20.00%
EPS This Year
-1.68
from -1.65
EPS Next Year
-2.80
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.1M | 152.3M | 193.2M | ||
| Avg | 52.7M | 63.2M | 71.1M | ||
| Low | 5.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 135.5% | 188.9% | 205.5% | ||
| Avg | 44.2% | 20.0% | 12.4% | ||
| Low | -83.9% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.98 | -1.73 | -0.60 | ||
| Avg | -1.68 | -2.80 | -2.25 | ||
| Low | -2.33 | -3.48 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.